A new lease on life for an HIV-neutralizing antibody class and vaccine target.
作者信息
Burton Dennis R
机构信息
Department of Immunology and Microbiology, IAVI Neutralizing Antibody Center, Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037;
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139.
出版信息
Proc Natl Acad Sci U S A. 2021 Feb 16;118(7). doi: 10.1073/pnas.2026390118.
Abstract
摘要
相似文献
1
A new lease on life for an HIV-neutralizing antibody class and vaccine target.
Proc Natl Acad Sci U S A. 2021 Feb 16;118(7). doi: 10.1073/pnas.2026390118.
2
Toward an antibody-based HIV-1 vaccine.
Annu Rev Med. 2010;61:135-52. doi: 10.1146/annurev.med.60.042507.164323.
3
In vivo protection by broadly neutralizing HIV antibodies.
Trends Microbiol. 2014 Oct;22(10):550-1. doi: 10.1016/j.tim.2014.08.006. Epub 2014 Aug 26.
4
HIV vaccine development--improving on natural immunity.
N Engl J Med. 2011 Sep 8;365(10):873-5. doi: 10.1056/NEJMp1107621.
5
HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
PLoS Pathog. 2014 May 22;10(5):e1004073. doi: 10.1371/journal.ppat.1004073. eCollection 2014 May.
6
Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?
Curr Opin HIV AIDS. 2009 Sep;4(5):347-51. doi: 10.1097/COH.0b013e32832f4a4d.
7
HIV Vaccines: One Step Closer.
Trends Mol Med. 2017 Jan;23(1):1-3. doi: 10.1016/j.molmed.2016.10.006. Epub 2016 Nov 23.
8
HIV. The modern era of HIV-1 vaccine development.
Science. 2015 Jul 10;349(6244):139-40. doi: 10.1126/science.aac7800.
9
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.
Nat Rev Immunol. 2013 Sep;13(9):693-701. doi: 10.1038/nri3516.
10
HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity.
Hum Vaccin. 2011 Apr;7(4):466-73. doi: 10.4161/hv.7.4.14123. Epub 2011 Apr 1.
引用本文的文献
1
Utilizing Machine Learning to Improve Neutralization Potency of an HIV-1 Antibody Targeting the gp41 N-Heptad Repeat.
ACS Chem Biol. 2025 Jul 18;20(7):1470-1480. doi: 10.1021/acschembio.5c00035. Epub 2025 Jun 20.
2
HIV-1 prehairpin intermediate inhibitors show efficacy independent of neutralization tier.
Proc Natl Acad Sci U S A. 2023 Feb 21;120(8):e2215792120. doi: 10.1073/pnas.2215792120. Epub 2023 Feb 16.
3
A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection.
Sci Transl Med. 2022 Mar 23;14(637):eabi9215. doi: 10.1126/scitranslmed.abi9215.
4
A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity.
J Virol. 2021 Jul 12;95(15):e0235020. doi: 10.1128/JVI.02350-20.
5
A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection.
bioRxiv. 2022 Jan 21:2021.03.30.437769. doi: 10.1101/2021.03.30.437769.
本文引用的文献
1
A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity.
J Virol. 2021 Jul 12;95(15):e0235020. doi: 10.1128/JVI.02350-20.
2
The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat.
Proc Natl Acad Sci U S A. 2021 Jan 19;118(3). doi: 10.1073/pnas.2018027118.
3
A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge.
Cell Host Microbe. 2019 Sep 11;26(3):336-346.e3. doi: 10.1016/j.chom.2019.08.014.
4
Antibody barriers to going viral.
J Exp Med. 2019 Oct 7;216(10):2226-2228. doi: 10.1084/jem.20191099. Epub 2019 Aug 23.
5
Passive and active antibody studies in primates to inform HIV vaccines.
Expert Rev Vaccines. 2018 Feb;17(2):127-144. doi: 10.1080/14760584.2018.1425619. Epub 2018 Jan 19.
6
Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.
Cell. 2016 Jun 16;165(7):1621-1631. doi: 10.1016/j.cell.2016.05.024.
7
Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.
Adv Biol. 2014;2014. doi: 10.1155/2014/157895. Epub 2014 Sep 9.
8
Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.
Sci Transl Med. 2014 Jul 2;6(243):243ra88. doi: 10.1126/scitranslmed.3008992.
9
Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis.
J Virol. 2013 May;87(9):5287-90. doi: 10.1128/JVI.00278-13. Epub 2013 Feb 13.
10
Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.
J Virol. 2010 Feb;84(3):1302-13. doi: 10.1128/JVI.01272-09. Epub 2009 Nov 11.
Zotero 插件